#India #Clinical Trials #Drug Development #Ahmedabad #Veeda Lifesciences

Veeda Group Evolves into Veeda Lifesciences

The Veeda Group has officially rebranded as Veeda Lifesciences, signaling a significant milestone in the company's evolution in the healthcare and pharmaceutical landscape. With a fresh logo and identity, Veeda aims to highlight its progressive shift from a contract research organization (CRO) focused on generics to a comprehensive drug development service provider that embraces innovation across various medication modalities, including generics and both chemical and biological new entities.

A New Identity for a New Era

The rebranding to Veeda Lifesciences represents the integration of several key components of the organization, unifying the former entities of Veeda Clinical Research, Health Data Specialists, and Bioneeds India. This strategic consolidation will allow Veeda to offer an extensive range of research services that encompass all phases of drug development. From the discovery stage through preclinical trials to final clinical development, Veeda Lifesciences will stand as a comprehensive provider for the life sciences and healthcare sectors.

Mahesh Bhalgat, the CEO of Veeda Lifesciences, emphasizes that this transformation aligns with the company’s mission to drive innovation and add value to its clients. Bhalgat remarks, “The new name and logo reflect our commitment to excellence and our focus on meeting the evolving needs of the pharmaceutical industry. We are dedicated to enhancing our service offerings to empower our clients in their quest for innovative solutions.”

Expanding Global Reach

Founded in India in 2004, Veeda Lifesciences boasts a footprint in five countries and conducts clinical trials in 26 nations, showcasing its commitment to global participation in the healthcare research field. The acquisition of Bioneeds in 2021 has further enhanced its preclinical service capabilities, allowing the organization to provide an even broader spectrum of services to well-regarded pharmaceutical sponsors and biotech firms around the world.

Veeda Lifesciences operates through four strategic business units:

• - Clinical Trials: Covering operations in Europe and India, focusing on patient-centric trials.
• - Healthy Volunteer Services: Conducting clinical bioanalysis in Gujarat, India, aimed at small molecules.
• - Biopharmaceutical Services: Based in Bangalore, this unit focuses on analytical characterization of biological products, cell line and process development, and clinical bioanalysis for large molecules.
• - Preclinical and Non-Clinical Testing: Located in Karnataka, this division emphasizes discovery research in chemistry and biology.

With a progressive CRO-CDMO model in the works, Veeda is also integrating cutting-edge AI technology and real-world data analytics, positioning itself as a frontrunner in the evolving landscape of drug development services.

Commitment to Quality and Innovation

Veeda Lifesciences is dedicated to upholding rigorous quality standards while investing in advanced technologies and a highly skilled workforce. This steadfast commitment ensures that the company remains at the forefront of drug development capabilities, enabling it to support its clients in delivering innovative therapies and high-quality generic medications to patients globally.

As the organization strides into this new chapter, the emphasis on embracing change and enhancing client collaboration remains paramount. Garassing these values will be critical as Veeda Lifesciences ventures forth, poised to leave a significant mark on the pharmaceutical industry.

The transformation into Veeda Lifesciences represents more than just a new name; it encapsulates the organization’s vision of innovation, excellence, and unwavering dedication to client satisfaction for years to come.

Conclusion

As Veeda Lifesciences embarks on its journey under this new identity, its clients can anticipate a robust service offering that aligns with contemporary industry demands. By persistently refining its operational capabilities and fostering innovation, the company aims to redefine the drug development landscape and meet the complex needs of the life sciences sector efficiently.